Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Vericel Corporation
Vericel Corporation News
Vericel Corporation Quantitative Score
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Vericel Corporation Financials
Table Compare
Compare VCEL metrics with: | |||
|---|---|---|---|
Earnings & Growth | VCEL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VCEL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VCEL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VCEL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Vericel Corporation Income
Vericel Corporation Balance Sheet
Vericel Corporation Cash Flow
Vericel Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Neutral |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Vericel Corporation Executives
| Name | Role |
|---|---|
| Mr. Dominick C. Colangelo Esq. | Chief Executive Officer, President & Director |
| Mr. Michael Halpin | Chief Operating Officer |
| Mr. Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer |
| Mr. Sean C. Flynn | Chief Legal Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Dominick C. Colangelo Esq. | Chief Executive Officer, President & Director | Male | 1964 | 1.56M |
| Mr. Michael Halpin | Chief Operating Officer | Male | 1962 | 819.17K |
| Mr. Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | Male | 1976 | 774.17K |
| Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. | Chief Medical Officer | 1962 | 705.13K | |
| Mr. Sean C. Flynn | Chief Legal Officer | Male | 1974 | 690.27K |
Vericel Corporation Insider Trades
| Date | 2 Jun |
| Name | Hopper Jonathan Mark |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 10000 |
| Date | 2 Jun |
| Name | Hopper Jonathan Mark |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 10000 |
| Date | 2 Jun |
| Name | Hopper Jonathan Mark |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 10000 |
| Date | 14 May |
| Name | Colangelo Dominick |
| Role | President and CEO |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 14062 |
| Date | 14 May |
| Name | Colangelo Dominick |
| Role | President and CEO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 14062 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Jun | Hopper Jonathan Mark | Chief Medical Officer | Acquired | M-Exempt | 10000 |
| 2 Jun | Hopper Jonathan Mark | Chief Medical Officer | Disposed | S-Sale | 10000 |
| 2 Jun | Hopper Jonathan Mark | Chief Medical Officer | Acquired | M-Exempt | 10000 |
| 14 May | Colangelo Dominick | President and CEO | Acquired | M-Exempt | 14062 |
| 14 May | Colangelo Dominick | President and CEO | Disposed | S-Sale | 14062 |